Abstract:
:We aimed to compare the evolution of estimated glomerular filtration rate (eGFR) in HIV-, HIV-HBV- and HBV-infected patients treated with tenofovir disoproxil fumarate (TDF). Three groups of patients receiving TDF > 12 months were recruited: 194 HIV-infected patients, 85 HIV-HBV-coinfected patients and 50 HBV-infected patients. eGFR was estimated using the Modification of the Diet in Renal Disease (MDRD) equation. Multivariate regression models were constructed to estimate factors associated with eGFR decrease from baseline. A total of 329 patients were studied. Median follow-up was 2.7 years. Median eGFR decrease was -4.9 (-16.6 to +7.2) mL/min/1.73 m(2) . After multivariate stepwise regression analysis, age (P = 0.0002), non-African origin (P < 0.0001), baseline eGFR (P < 0.0001) and TDF duration (P = 0.02) were associated with eGFR decrease in the whole population, while hypertension, diabetes and type of infection were not. Age (P < 0.0001), non-African origin (P = 0.0004), baseline eGFR (P < 0.0001) and TDF duration (P = 0.007) remained associated with eGFR decline in HIV and HIV-HBV-infected patients, while other variables including HIV risk factor, CDC stage, CD4 and HIV-RNA levels were not. Age (P = 0.03), non-African origin (P = 0.004), baseline eGFR (P < 0.0001) and baseline HBV-DNA > 2000 IU/mL (P = 0.04) were associated with eGFR decline in HBV and HIV-HBV-infected patients, while other variables including HBV risk factor and fibrosis stage were not. Estimated glomerular filtration rate decline under TDF therapy appears mainly associated with older age, non-African origin, higher baseline eGFR and longer TDF administration but not with the type of viral infection. Regular follow-up of renal function, especially tubular function is recommended during TDF therapy.
journal_name
J Viral Hepatjournal_title
Journal of viral hepatitisauthors
Pradat P,Le Pogam MA,Okon JB,Trolliet P,Miailhes P,Brochier C,Maynard M,Bailly F,Zoulim F,Cotte Ldoi
10.1111/jvh.12088subject
Has Abstractpub_date
2013-09-01 00:00:00pages
650-7issue
9eissn
1352-0504issn
1365-2893journal_volume
20pub_type
杂志文章abstract::In this pilot study, we evaluated the efficacy of interferon-alpha (IFN) plus Thymosin-alpha 1 (TA1) to that of IFN alone in naive patients with chronic hepatitis C. Twenty-two patients were randomized to receive interferon-alpha 2b (3 million units three times a week) plus thymosin-alpha l (900 microg/m2 body surface...
journal_title:Journal of viral hepatitis
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.1046/j.1365-2893.2003.00470.x
更新日期:2004-01-01 00:00:00
abstract::Many patients chronically infected by hepatitis C virus (HCV) experience symptoms like fatigue, dyspnea and reduced physical activity. However, in many patients, these symptoms are not proportional to the liver involvement and could resemble symptoms of chronic heart failure. To our knowledge, no study evaluated serum...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2009.01237.x
更新日期:2010-12-01 00:00:00
abstract::Sustained virologic response (SVR) is the standard measure for evaluating response to therapy in patients with chronic hepatitis C (CHC). The aim of this study was to prospectively assess the durability of SVR in the pivotal studies of peginterferon (PEG-IFN) α-2b or IFN α-2b. We conducted two phase 3b long-term follo...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1111/jvh.12074
更新日期:2013-08-01 00:00:00
abstract::Diabetes mellitus has been reported to have an increased prevalence and to be associated with more severe fibrosis in patients with chronic hepatitis C. We evaluated the prevalence of diabetes mellitus in patients with chronic hepatitis B or C as well as the possible association between presence of diabetes and extent...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2005.00677.x
更新日期:2006-05-01 00:00:00
abstract::Interferon (IFN)-alpha is a family of antiviral proteins encoded by different genes. The biological significance of the existence of various IFN-alpha subtypes is not clear. We have investigated the interferon system in chronic hepatitis C virus (HCV) infection, a disease that responds to interferon-alpha2 therapy in ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1046/j.1365-2893.2001.00273.x
更新日期:2001-03-01 00:00:00
abstract::Approximately 5% of the healthy adult population respond inadequately to the commercial recombinant hepatitis B vaccines. As the recombinant vaccines all have an aluminium-based adjuvant, we tried to enhance the immune response by adding a cytokine-based adjuvant. This new adjuvant AI20, containing 20 μg recombinant h...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,随机对照试验
doi:10.1111/jvh.12909
更新日期:2018-09-01 00:00:00
abstract::Hepatitis B virus (HBV) infection induces a wide range of chronic liver injury. The mechanism by which HBV evades the immune surveillance system remains obscure. Plasmacytoid dendritic cells (pDCs) seem to be the major endogenous interferon (IFN)-alpha producers and represent one of the most important cell types in th...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2006.00819.x
更新日期:2007-04-01 00:00:00
abstract::A large number of studies have reported on spontaneous viral clearance rates in acute hepatitis C infection, however most have been small, and reported rates have varied quite widely. To improve the precision of the estimated rate of spontaneous viral clearance, a systematic review was conducted of longitudinal studie...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/j.1365-2893.2005.00651.x
更新日期:2006-01-01 00:00:00
abstract::In patients with chronic hepatitis B (CHB), long-term effects of tenofovir disoproxil fumarate (TDF) on renal function have been controversial. This study aimed to analyse the real-world long-term effects of TDF on renal function in Korean patients with CHB. We analysed a cohort of 640 treatment-naïve patients with CH...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13222
更新日期:2020-03-01 00:00:00
abstract::Both hepatitis B and hepatitis C viruses (HBV and HCV) cause chronic infections worldwide that are associated with development of liver diseases ranging from mild liver inflammation to hepatocellular carcinomas. While efficient preventive vaccines are available for HBV, efforts are ongoing to develop one in case of HC...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/j.1365-2893.2007.00922.x
更新日期:2007-11-01 00:00:00
abstract::Better understanding of hepatitis B virus (HBV) replication, natural history and the immunopathogenesis of chronic hepatitis B, together with the introduction of effective agents with different mechanisms of action are the basis for better therapeutic strategies against chronic hepatitis B. Among currently available d...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1046/j.1365-2893.2002.00388.x
更新日期:2002-11-01 00:00:00
abstract::The establishment of an in vitro system for hepatitis C virus (HCV) propagation is essential to characterize virus replication, virus persistence and viral pathogenicity. The aim was to establish HCV replication in HepG2 cells by gene transfer of infectious HCV cDNA. First, several gene transfer methods were evaluated...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.1997.tb00162.x
更新日期:1997-01-01 00:00:00
abstract::We compared sustained virological response (SVR) in chronic hepatitis C patients with severe fibrosis treated with pegylated interferon (Peg-IFN) alpha-2b 1.5 microg/kg/week or 0.75 microg/kg/week in combination with ribavirin 800 mg/day for 48 weeks. This was a multicentre randomized controlled study. SVR was observe...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1111/j.1365-2893.2006.00768.x
更新日期:2006-12-01 00:00:00
abstract::The human La (hLa) protein functions in RNA metabolism and is activated by casein kinase 2 (CK2) phosphorylation. Hepatitis B virus (HBV) can exploit hLa to stabilize its RNA and promote its pathogenesis. To enhance our knowledge of host molecular pathways involved in HBV pathogenesis, a bioinformatic approach was use...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2012.01626.x
更新日期:2013-01-01 00:00:00
abstract::Despite the availability of a preventative vaccine, chronic hepatitis B (CHB) remains a global healthcare challenge with the risk of disease progression due to cirrhosis and hepatocellular carcinoma. Although current treatment strategies, interferon and nucleos(t)ide analogues have contributed to reducing morbidity an...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/jvh.13040
更新日期:2019-01-01 00:00:00
abstract::We evaluated the shift in the characteristics of people who received interferon-based hepatitis C virus (HCV) treatments and those who received recently introduced direct-acting antivirals (DAAs) in British Columbia (BC), Canada. The BC Hepatitis Testers Cohort includes 1.5 million individuals tested for HCV or HIV, o...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12684
更新日期:2017-08-01 00:00:00
abstract::The ECHO model was developed to expand access to medical care for populations with HCV infection in underserved areas. We aimed to compare HCV treatment outcomes in community-based clinics with the Austral University Hospital (AUH) and to assess improvement in physician knowledge and skills. In October 2015, we establ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13172
更新日期:2019-11-01 00:00:00
abstract::The aims of the present study were to assess initial virological response (IVR) to adefovir (ADV) treatment for chronic hepatitis B, to identify patients with suboptimal response and to determine the incidence of ADV-resistant mutants. All patients treated with ADV for at least 12 months were evaluated for virological...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2007.00966.x
更新日期:2008-05-01 00:00:00
abstract::The triglycerides × glucose (TyG) index is a recently proposed surrogate marker of insulin resistance (IR), calculated from fasting plasma triglyceride and glucose concentrations. We tested the host and viral factors associated with Tyg and homeostasis model assessment (HOMA) scores, comparing their associations with ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2011.01439.x
更新日期:2011-07-01 00:00:00
abstract::In Italy, HDV infection endemicity has greatly decreased overtime. Migratory flow may change this scenario as migrants often come from high HDV endemicity areas. Here, we studied characteristics of HDV infection in Italy, particularly addressed to the birth area of subjects. Chronic HBsAg carriers consecutively referr...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13310
更新日期:2020-09-01 00:00:00
abstract::We aimed to investigate the ability of HBsAg plasma level kinetics to predict therapy response by studying 23 children with infancy-acquired chronic hepatitis B (CHB) during combination sequential therapy with lead-in lamivudine (LAM) and add-on interferon-α (IFN-α) [5 responders (R = anti-HBs seroconversion) and 18 n...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12316
更新日期:2015-04-01 00:00:00
abstract::Dendritic cells (DCs) in chronic hepatitis C patients display impaired function, although the details remain unclear. To investigate the hepatitis C virus (HCV) protein that has the most impact on DC function, we compared five recombinant proteins and seven HCV protein genes in modulating DC phenotype and function. Im...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2009.01213.x
更新日期:2010-08-01 00:00:00
abstract::In previous hepatitis C virus (HCV) treatment studies, Black patients not only had a lower sustained viral response (SVR) rate to interferon and ribavirin (RBV) than non-Black patients but also a higher frequency of HCV genotype 1 (GT-1) infection. The aim of this community-based study was to determine whether Black p...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,多中心研究
doi:10.1111/j.1365-2893.2005.00682.x
更新日期:2006-04-01 00:00:00
abstract::Through molecular virological testing it is now clear that HCV reinfection of the allograft is virtually universal in liver transplant recipients. Although histopathological recurrence of hepatitis C occurs in the majority of patients, it is absent in a substantial minority. To date, no prognostic factors, other than ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/j.1365-2893.1997.tb00172.x
更新日期:1997-01-01 00:00:00
abstract::With the approval of 2 direct-acting antivirals (DAAs) in 2011 and anticipation of interferon (IFN)-free regimens, more hepatitis C virus (HCV) chronically infected patients are now seeking treatment. To describe the characteristics of newly referred HCV patients in 2011-2012 (Era-2) and compare them to those seen in ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12343
更新日期:2015-05-01 00:00:00
abstract::Even with pegylated (PEG) interferons (IFN), therapy of chronic hepatitis C (genotype 1) remains unsatisfactory. The initial viral response to IFN identifies patients infected with IFN resistant viruses not responding to standard IFN/ribavirin therapy. The impact of primary IFN unresponsiveness for PEG-IFN-alpha-2a/ri...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1046/j.1365-2893.2003.00396.x
更新日期:2003-01-01 00:00:00
abstract::The non-structural (NS)5A protein of hepatitis C virus (HCV) is cleaved, after translation, by the NS3-encoded zinc-dependent serine proteinase, from the NS4B protein upstream and the NS5B protein downstream. The released, mature NS5A protein is a 56 000 MW phosphoprotein (p56), which also exists within infected cells...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1046/j.1365-2893.1999.00185.x
更新日期:1999-09-01 00:00:00
abstract::Patients with chronic hepatitis B (HBsAg-positive) are at risk of viral reactivation if rituximab is administered without antiviral treatment, a potentially fatal complication of treatment. Patients with so-called 'resolved hepatitis B virus infection' (HBsAg-negative/cAb-positive) may also be at risk. We performed a ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,meta分析,评审
doi:10.1111/jvh.12402
更新日期:2015-10-01 00:00:00
abstract::Virus-like particles encapsulating HBV-RNA represent a serum biomarker for assessing viral replication activity in clinical practice. However, baseline levels of serum HBV-RNA and their associations with viral replicative intermediates and liver disease in phases of chronic hepatitis B remain unknown. In this cross-se...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12908
更新日期:2018-09-01 00:00:00
abstract::Recently, attention has been focussed on adiponectin and its changes in different types of chronic liver disease. Its relation to hepatic fibrosis and insulin resistance in post-hepatitis liver disease is not clear. The aim of this study was to clarify the adiponectin changes in genotype 4 hepatitis C virus (HCV)-infe...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2009.01096.x
更新日期:2009-10-01 00:00:00